Top

The Patient - Patient-Centered Outcomes Research

Published in:

Open Access 01-06-2015 | Original Research Article

Unmet Needs Associated with Attention-Deficit/Hyperactivity Disorder in Eight European Countries as Reported by Caregivers and Adolescents: Results from Qualitative Research

Authors: Vanja Sikirica, Emuella Flood, C. Noelle Dietrich, Javier Quintero, Val Harpin, Paul Hodgkins, Klaus Skrodzki, Kathleen Beusterien, M. Haim Erder

Published in: The Patient - Patient-Centered Outcomes Research | Issue 3/2015

Abstract

Introduction

Attention-deficit/hyperactivity disorder (ADHD) is a neurobehavioral disorder characterized by inattention, impulsivity, and hyperactivity, the levels of which are inappropriately high for an individual’s developmental age.

Objective

The objective of this study was to explore the unmet needs of children/adolescents with ADHD and their caregivers in eight European countries.

Methods

Semi-structured interviews with 38 caregivers of children/adolescents (aged 6–17 years) with ADHD and no or less serious comorbidities and 28 adolescents (aged 13–17 years) with ADHD and no or less serious comorbidities were conducted, audio-recorded, transcribed into English, and coded for analysis.

Results

Caregivers reported their own ADHD-related issues, including making personal accommodations, such as limiting activities and spending extra time/effort caring for their child/adolescent, social impacts, and strained relationships. Medication was generally considered helpful; however, most children experience core ADHD symptoms while on medication (reported by 88 % of caregivers and 100 % of adolescents). Adolescents often reported schoolwork difficulties (96 %) and peer issues (75 %), while caregivers reported school issues (84 %) and peer difficulties (79 %). Caregivers reported minimal ADHD education and community support. Caregivers (29 %) and adolescents (54 %) desired medication that better controlled symptoms but had concerns about being oversubdued. Caregivers reported concerns about adverse effects (21 %).

Conclusions

European caregivers of children/adolescents with ADHD identified multiple unmet needs, which persist despite treatment. Adolescents noted impacts on school and social interactions consistent with caregivers. Future research is needed to quantify the study findings, and, ultimately, ease the impact of ADHD on patients and their caregivers.

Available only for authorised users

Polanczyk G, Silva de Lima M, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–8.CrossRefPubMed

Preuss U, Ralston SJ, Baldursson G, Falissard B, Lorenzo MJ, Rodrigues Pereira R, et al. Study design, baseline patient characteristics and intervention in a cross-cultural framework: results from the ADORE study. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I4–14.CrossRefPubMed

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, et al. European clinical guidelines for hyperkinetic disorder: first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):7–30.

Health Ministry of Spain. Guía de Práctica Clínica sobre el Trastorno por Déficit de Atención con Hiperactividad (TDAH) en Niños y Adolescentes. Available at: http://www.anhipa.com/Documentos/Guiaclinica.pdf. Accessed 2 Aug 2013.

NICE (National Institute for Health and Clinical Excellence). Clinical Guidance 72. Attention deficit hyperactivity disorder (ADHD): diagnosis and management of ADHD in children, young people and adults. Available at: http://www.nice.org.uk/nicemedia/live/12061/42059/42059.pdf. Accessed 2 Aug 2013.

Seixas M, Weiss M, Müller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012;26:753–65.CrossRefPubMed

Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843–66.CrossRefPubMed

Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Döpfner M, Hollis C, et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83–105.CrossRefPubMedCentralPubMed

Escobar R, Soutullo CA, Hervas A, Gastaminza X, Polavieja P, Gilaberte I. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Pediatrics. 2005;116:e364–9.CrossRefPubMed

10.

Staikova E, Gomes H, Tartter V, McCabe A, Halperin JM. Pragmatic deficits and social impairment in children with ADHD. J Child Psychol Psychiatry. 2013;54:1276–83.CrossRef

11.

Varni JW, Burwinkle TM. The PedsQL^TM as a patient-reported outcome in children and adolescents with attention-deficit/hyperactivity disorder: a population-based study. Health Qual Life Outcomes. 2006;4:26.CrossRefPubMedCentralPubMed

12.

Harpin VA. The effect of ADHD on the life of an individual, their family, and community from preschool to adult life. Arch Dis Child. 2005;90(Suppl 1):i2–7.CrossRefPubMedCentralPubMed

13.

Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, et al. Carer burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry. 2012;51:879–88.CrossRefPubMed

14.

Kvist AP, Nielsen HS, Simonsen M. The effects of children’s ADHD on parents’ relationship dissolution and labor supply. Available at: http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1958748. Accessed 2 Aug 2013.

15.

Wymbs BT, Pelham WE, Molina BS, Gnagy EM, Wilson TK, Greenhouse JB. Rate and predictors of divorce among parents of youths with ADHD. J Consult Clin Psychol. 2008;76:735–44.CrossRefPubMedCentralPubMed

16.

Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, et al. In their own words: adolescent views on ADHD and their evolving role managing medication. Acad Pediatr. 2012;12:53–61.CrossRefPubMedCentralPubMed

17.

FDA (Food and Drug Administration). Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. December 2009. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf. Accessed 10 July 2014.

18.

Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. Research methods for clinical and health psychology. London: Sage; 2004. p. 56–68.

19.

Coghill D, Soutullo C, D’Aubuisson C, Preuss U, Lindback T, Silverberg M, et al. Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child Adolesc Psychiatry Ment Health. 2008;2:31.CrossRefPubMedCentralPubMed

20.

Factor PI, Rosen PJ, Reyes RA. The relation of poor emotional awareness and externalizing behavior among children with ADHD. J Atten Disord. 2013 [Epub ahead of print].

21.

Svanborg P, Thernlund G, Gustafsson PA, Hägglöf B, Schacht A, Kadesjö B. Atomoxetine improves patient and family coping in attention deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled study in Swedish children and adolescents. Eur Child Adolesc Psychiatry. 2009;18:725–35.CrossRefPubMedCentralPubMed

Title: Unmet Needs Associated with Attention-Deficit/Hyperactivity Disorder in Eight European Countries as Reported by Caregivers and Adolescents: Results from Qualitative Research
Authors: Vanja Sikirica
Emuella Flood
C. Noelle Dietrich
Javier Quintero
Val Harpin
Paul Hodgkins
Klaus Skrodzki
Kathleen Beusterien
M. Haim Erder
Publication date: 01-06-2015
Publisher: Springer International Publishing
Published in: The Patient - Patient-Centered Outcomes Research / Issue 3/2015
Print ISSN: 1178-1653
Electronic ISSN: 1178-1661
DOI: https://doi.org/10.1007/s40271-014-0083-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2015

Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial

Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

Walking in the Shoes of Patients, Not Just in Their Genes: A Patient-Centered Approach to Genomic Medicine

Improving the Validity of Stated-Preference Data in Health Research: The Potential of the Time-to-Think Approach

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials